Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.
暂无分享,去创建一个
A. Jakubowiak | T. Zimmerman | A. Singhal | W. Bensinger | D. Siegel | K. Anderson | J. V. Tornout | Carol Zhao